36 results about "Homocystine" patented technology

A composition comprising an amphoteric or pseudo-amphoteric agent and a polyhydroxy alpha hydroxyacid existing as a free acid, lactone, or salt, and isomeric or non-isomeric forms thereof is provided. The amphoteric or pseudo-amphoteric agent can be selected from amino acids, dipeptides, aminoaldonic acid, aminouronic acid, lauryl aminoproplyglycine, aminoaldaric acid, neuraminic acid desulfated heparin, deacetylated hyaluronic acid, hyalobiuronic acid, chondrosine, deacetylated chondroitin, creatine, creatinine, hydroxyproline, homocysteine, homocystine, homoserine, ornithine, citrulline, phosphatidylserine, and sphingomyelin. The composition may contain other additives, including cosmetic or pharmaceutical agents for topical treatment of dermatological disorders.

The invention discloses a reactive-type fluorescence probe for distinguishing sulfydryl compounds, wherein the structure of the fluorescence probe is represented as the formula (I). R1, R2, R3 and R4 are independently selected from one of hydrogen, a C1-C8 alkyl group and a C3-C8 cycloalkyl group, and X is independently selected from halogens; or the R1 and the R4 and/or the R2 and the R3 can form a ring. The invention also discloses a synthesis method and an application of the fluorescence probe. The fluorescence probe is low in molecular weight, is high in fluorescent quantum yield, has good cytocompatibility, can generate different fluorescence enhancement signals when being reacted respectively with cysteine and homocystine, can distinguish and recognize the cysteine and homocystine well, has good stability and is easy to prepare.

The present disclosure relates to erythroid cells that have been engineered to express a homocysteine reducing polypeptide, or a variant thereof, or a homocysteine degrading polypeptide, or a variant thereof. The engineered erythroid cells may further comprise an amino acid transporter, for example a homocysteine transporter or a serine transporter, or a cystathionine degrading polypeptide. The engineered erythroid cells of the present disclosure are useful in reducing the level of homocysteine in a subject. The engineered erythroid cells of the present disclosure are further useful in methods of treating homocystinuria.

The invention discloses selenium-enriched ecological bacterial fertilizer. The selenium-enriched ecological bacterial fertilizer is prepared from paddy rice straws, biogas slurry, mushroom residues, compound bacteria, potassium selenite, brown sugar, ammonium carbonate, monoammonium phosphate, potassium chloride, selenium humate, selenium-substituted homocystine, selenium ore powder, itaconic acid, dibutyl carboxyl toluene, a silane coupling agent KH-57, pentamethyl diethylene triamine, o-phenyl benzoic acid, polyvinyl alcohol, attapulgite, soya lecithin, sodium alginate and chitin through compound fertilizer granule preparation, coating material liquid preparation, fertilizer granule coating and drying. The ecological bacterial fertilizer can improve the yield of Chinese cabbage and the content of selenium.

The invention discloses a synthesis method of DL-homocysteine thiolactone hydrochloride. A DL-homocystine is prepared into a catholyte with a hydrochloric acid solution as a medium, and electrolysis is conducted in an electrolysis tank to obtain the DL-homocysteine thiolactone hydrochloride, wherein according to a cathode electrode, a roughened glass carbon electrode serves as a base material, andthe surface of the base material is covered with lead-bismuth alloy. The method can be used for improving the yield of the DL-homocysteine thiolactone hydrochloride.

The invention provides a post-treatment method of a homocystine reaction solution, and relates to the technical field of homocystine preparation. The post-treatment method of the homocystine reactionsolution comprises the following steps: adsorbing the homocystine reaction solution in acid ion exchange resin, performing primary elution on the adsorption ion exchange resin through water, obtainingeluent and deacidified ion exchange resin, and wherein the eluent comprises recycled sulfuric acid and hydrobromic acid; and carrying out secondary elution on the deacidified ion exchange resin by using an acid eluent or an alkali eluent to obtain an acid eluent or an alkali eluent, the acid eluent or the alkali eluent containing homocystine. According to the post-treatment method, sulfuric acidand hydrobromic acid are weak in adsorption capacity in acidic ion resin, and are easily eluted with water to be separated from the reaction solution so that a large amount of waste salt generated byneutralizing the reaction liquid with alkali liquor is avoided, and the method is green and environment-friendly; complex devices are not needed, and the cost is low.

The present invention provides a method of PEGylating a human truncated cystathionine β-synthase protein containing a mutation of a cysteine to a serine at amino acid position 15 (htCBS C15S). The htCBS C15S was PEGylated with one of 5 kDa, 10 kDa, or 20 kDa NHS ester PEG molecules. In-process monitoring of the PEGylation process was used in the method to reduce levels of unPEGylated htCBS C15S and htCBS C15S with insufficient PEGylation. Administration of the PEGylated htCBS C15S had efficacy throughout the course of treatment for homocystinuria.

Disclosed is the synthesis of N-methyl-homocystines and the use thereof.

The present invention discloses a DL-homocysteic acid preparation method comprising the following steps: (1) dissolving DL-homocystine in an appropriate amount of hydrochloric acid, firstly heating to the temperature of 50 DEG C-70 DEG C, then adding dropwise sodium hypochlorite, after the addition is complete, then secondly heating to the temperature of 75 DEG C-85 DEG C for reaction for 1 to 3 hours to obtain a reaction solution; and (2) concentrating the reaction solution obtained in step (1) to a small volume, then adding an appropriate amount ethanol, crystallizing, then filtering to obtain a solid crystal, and drying thee solid crystal to obtain a DL-homocysteic acid desired product. The new method for preparation of the DL-homocysteic acid by reaction of the DL-homocystine and the sodium hypochlorite in the hydrochloric acid avoids use of bromine as a reactant, and avoids pollution generated by the use of bromine, and the DL-homocysteic acid product prepared by the method is high in quality and has the purity more than 98%.

The invention discloses a synthesis method of thionyl diacetic acid. The method mainly comprises the following steps: dissolving homocystine in hydrochloric acid to obtain a catholyte, and carrying out an electroreduction reaction in an electrolytic cell to obtain homocysteine hydrochloride; dissolving the homocysteine hydrochloride and chloroacetic acid in water, adding methanol, dropwise addinga catalyst and a dehydrating agent, stirring to react for 2-5 hours, cooling the reaction product, filtering the reaction product to separate out homoserine lactone hydrochloride, and carrying out reduced pressure distillation on the filtrate to obtain methyl mercaptoacetate; and dissolving the methyl mercaptoacetate and the halogenated methyl acetate in methanol, controlling the temperature to be25-50 DEG C, reacting for 6-12 hours, carrying out reduced pressure distillation, adding dilute sulfuric acid, heating the mixture to 50-80 DEG C, and separating and purifying the mixture to obtain the thiodiacetic acid. According to the synthesis method of the thionyl diacetic acid, the yield can be effectively improved.

The present disclosure provides formulations for a drug product comprising a PEGylated CBS protein having the amino acid sequence of SEQ ID NO: 1. Dosages and dosing regimens are provided for treatment of homocystinuria in a subject in need thereof. Additionally, the dosages and dosing regimens are also provided to reduce the level of homocysteine (Hcy) or increase the levels of cysteine (Cys) and/or cystathionine (Cth) in a subject in need thereof.

The invention relates to a drug composition containing amlodipine, atorvastatin and folic acid and a new application thereof in preparing drugs for treating the HHCY-hyperhomocysteinemia and the elevated homocysteine. The composition of the amlodipine or a levoamlodipine, the atorvastatin and the folic acid can further reduce the Hcy level, and the effect is superior to that of single drug, so that the composition of the amlodipine or the levoamlodipine, the atorvastatin and the folic acid can not only lower the Hcy level, but also has synergetic effect on reducing the Hcy damages. The composition of the invention is a selection for treating Hcy, which provides a more effective treatment protocol for treating high homocysteine. The invention belongs to the pharmaceutical field.